A novel technique using lidocaine 2% topical gel for peristomal dermatitis.

J Am Acad Dermatol

Division of Dermatology, University of Kansas Medical Center, Kansas City, Missouri. Electronic address:

Published: September 2023

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.02.077DOI Listing

Publication Analysis

Top Keywords

novel technique
4
technique lidocaine
4
lidocaine topical
4
topical gel
4
gel peristomal
4
peristomal dermatitis
4
novel
1
lidocaine
1
topical
1
gel
1

Similar Publications

Resistance training (RT) load and volume are considered crucial variables to appropriately prescribe and manage for eliciting the targeted acute responses (i.e., minimizing neuromuscular fatigue) and chronic adaptations (i.

View Article and Find Full Text PDF

Itching tends to worsen at night in patients with itchy skin diseases, such as atopic dermatitis. Unconscious scratching during sleep can exacerbate symptoms, cause sleep disturbances, or reduce quality of life. Therefore, evaluating nocturnal scratching behaviour is important for better patient care.

View Article and Find Full Text PDF

Background: Stroke has emerged as an escalating public health challenge among middle-aged and older individuals in China, closely linked to glycolipid metabolic abnormalities. The Hemoglobin A1c/High-Density Lipoprotein Cholesterol (HbA1c/HDL-C) ratio, an integrated marker of glycolipid homeostasis, may serve as a novel predictor of stroke risk.

Methods: Our investigation utilized data from the China Health and Retirement Longitudinal Study cohort (2011-2018).

View Article and Find Full Text PDF

Background: Ovarian cancer (OC), particularly high-grade serous ovarian carcinoma (HGSOC), is the leading cause of mortality from gynecological malignancies worldwide. Despite the initial effectiveness of treatment, acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPis) represents a major challenge for the clinical management of HGSOC, highlighting the necessity for the development of novel therapeutic strategies. This study investigated the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a pivotal regulator of glycolysis, in PARPi resistance and explored its potential as a therapeutic target to overcome PARPi resistance.

View Article and Find Full Text PDF

Background: SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!